Montelukast in asthmatic patients 6 years-14 years old with an FEV 1 > 75%

Current Medical Research and Opinion

Volumn 20, Issue 10, 2004, Pages 1651-1659

  Becker, Allan ^a,c   Swern, Arlene ^b   Tozzi, Carol A ^b   Yu, Qinfen ^b   Reiss, Theodore ^b   Knorr, Barbara ^b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b MERCK RESEARCH LABORATORIES   (United States)

^c CHILDREN S HOSPITAL RESEARCH INSTITUTE OF MANITOBA   (Canada)

Author keywords

Asthma, pediatric; Efficacy; FEV1; Leukotriene receptor antagonist; Quality of life

Indexed keywords

LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; PLACEBO; SALBUTAMOL;

ADOLESCENT; ASTHMA; CHILD; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PEAK EXPIRATORY FLOW; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL;

ACETATES; ADOLESCENT; ANTI-ASTHMATIC AGENTS; ASTHMA; CHILD; DOUBLE-BLIND METHOD; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; PLACEBOS; QUINOLINES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 7744244569     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079904X4644     Document Type: Conference Paper

References (33)

1. Mannino DM, Homa DM, Akinbami LJ, et al. Surveillance for asthma - United States, 1980-1999. MMWR Surveill Summ 2002;29;51(1):1-13
2. Juniper EF, Guyatt GH, Feeny DH, et al. Measuring quality of life in children with asthma. Qual Life Res 1996;5(1):35-46
3. National Asthma Education and Prevention Program. Expert panel report 2: guidelines for the diagnosis and management of asthma. In: NIH Publication No. 97-4051. Bethesda (MD): National Institutes of Health; 1997
4. Global Initiative for Asthma. Pocket guide for asthma management and prevention. In: NIH Publication No. 96-3659B. Bethesda (MD): National Institutes of Health; 1998
5. Boulet L-P, Becker A, Berube D, et al. Canadian asthma consensus report, 1999. Can Med Assoc J 1999;161 (Suppl 11):51-61 [review]
6. Boulet L-P, Bai TR, Becker A, et al. What is new since the last (1999) Canadian asthma consensus guidelines? Can Respir J 2001;8(Suppl A):5A-27A
7. Beasley R, Roche WR, Roberts JA, Holgate ST. Cellular events in the bronchi in mild asthma and after bronchoprovocation. Am Rev Respir Dis 1989;139:806-17
8. Lemanske RF. Origins and treatment of airway inflammation in childhood asthma. Ped Pulmonol Suppl 2001;21:17-25
9. Djukanovic R. Airway inflammation in asthma and its consequences: implications for treatment in children and adults. J Allergy Clin Immunol 2002;109:S539-S548
10. Holgate ST, Bradding P, Sampson AP. Leukotriene antagonists and synthesis inhibitors: new directions in asthma therapy. J Allergy Clin Immunol 1996;98:1-13
11. Drazen JM, Israel E, O'Byrne PM. Treatment of asthma with drugs modifying the leukotriene pathway. New Engl J Med 1999;340:197-206
12. Knorr B, Matz J, Bernstein JA, et al. Montelukast for chronic asthma in 6- to 14-year-old children. J Am Med Assoc 1998;279:1181-6
13. Knorr B, Franchi LM, Bisgaard H, et al. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics 2001;108 (3):E48
14. Reiss TF, Chervinsky P, Dockhorn RJ, et al. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma. Arch Intern Med 1998;158:1213-20
15. Kemp JP, Dockhorn RJ, Shapiro GG, et al. Montelukast once daily inhibits exercise-induced bronchoconstriction in 6- to 14-year-old children with asthma. J Pediatr 1998;133:424-8
16. Melo RE, Sole D, Naspitz CK. Exercise-induced bronchoconstriction in children: montelukast attenuates the immediate-phase and late phase responses. J Allergy Clin Immunol 2003;111:301-7
17. Leff JA, Busse WW, Pearlman D, et al. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. New Engl J Med 1998;339(3):147-52
18. Bukstein DA, Luskin AT, Bernstein A. 'Real World' effectiveness of daily controller medicine in children with mild persistent asthma. Ann Allergy Asthma Immunol 2003;90:543-9
19. Barnes N, Wei LX, Reiss TF, et al. Analysis of montelukast in mild persistent asthmatic patients with near-normal lung function. Respir Med 2001;95:379-86
20. Karaman O, Sunneli L, Uzuner N, et al. Evaluation of montelukast in 8 to 14 year old children with mild persistent asthma and compared with inhaled corticosteroids. Allergol et Immunopathol 2004;32:21-7
21. Santanello NC, Demuro-Mercon C, Davies G, et al. Validation of a pediatric asthma caregiver diary. J Allergy Clin Immunol 2000;106(5):861-6
22. Singulair® (montelukast sodium) tablets, chewable tablets, and oral granules. Merck & Co., Inc. Whitehouse Station, NJ, 2002
23. Frieman, J, Chalmers TC, Smith H, Kuebler R. The importance of beta, the type II error and sample size in the design and interpretation of the randomized clinical trial. New Engl J Med 1978;299:690-4
24. Juniper EF, Kline PA, Vanzieleghem MA, et al. Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics. Am Rev Respir Dis 1990;142(4):832-6
25. Wallin A, Sandström T, Söderberg M, et al. The effects of regular inhaled formoterol, budesonide, and placebo on mucosal inflammation and clinical indices in mild asthma. Am J Respir Crit Care Med 1999;159:79-86
26. Kemp JP, Minkwitz MC, Bonuccelli CM, Warren MS. Therapeutic effect of zafirlukast as monotherapy in steroid-naive patients with severe persistent asthma. Chest 1999;115(2):336-42
27. MacKenzie CA, Weinberg EG, Tabachnik E, et al. A placebo controlled trial of fluticasone propionate in asthmatic children. Eur J Pediatr 1993;152:856-60
28. Tinkelman DG, Reed CE, Nelson HS, Offord KP. Aerosol beclomethasone dipropionate compared with theophylline as primary treatment of chronic, mild to moderately severe asthma in children. Pediatrics 1993;92:64-77
29. Shapiro BB, Konig P. Cromolyn sodium: a review. Pharmacotherapy 1985;5:156-70
30. Strunk RC, Sternberg AL, Bacharier LB, et al. Nocturnal awakenings caused by asthma in children with mild-to-moderate asthma in the Childhood Asthma Management Program. J Allergy Clin Immunol 2002;110:395-403
31. Urschitz MS, Guenther A, Eggebrecht E, et al. Snoring, intermittent hypoxia and academic performance in primary school children. Am J Respir Crit Care Med 2003;168:464-8
32. Bousquet J, Chanez P, Lacoste JY, et al. Eosinophilic inflammation in asthma. New Engl J Med 1990;323:1033-9
33. Asthma: a follow-up statement from an international paediatric asthma consensus group. Arch Dis Child 1992;67:240-8